Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide.

Abstract

The JNK pathway is known to be activated in several tissues in the diabetic state, and is possibly involved in the development of insulin resistance and suppression of insulin biosynthesis. Here we show a potential new therapy for diabetes using cell-permeable JNK-inhibitory peptide. Intraperitoneal administration of the peptide led to its transduction into various tissues in vivo, and this treatment markedly improved insulin resistance and ameliorated glucose tolerance in diabetic mice. These data indicate that the JNK pathway is critically involved in diabetes and that the cell-permeable JNK-inhibitory peptide may have promise as a new therapeutic agent for diabetes.

• Authors: Hideaki Kaneto, Yoshihisa Nakatani, Takeshi Miyatsuka, Dan Kawamori, Taka-aki Matsuoka, Munehide Matsuhisa, Yoshitaka Kajimoto, Hidenori Ichijo, Yoshimitsu Yamasaki, Masatsugu Hori
• Journal: Nature medicine (Nat Med) Vol. 10 Issue 10 Pg. 1128-32 (Oct 2004) ISSN: 1078-8956 [Print] United States
• PMID: 15448687 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Peptides
• Mitogen-Activated Protein Kinase 8
• Fluorescein-5-isothiocyanate

Topics

• Amino Acid Sequence
• Animals
• Blotting, Western
• Diabetes Mellitus, Type 2 (therapy)
• Fluorescein-5-isothiocyanate
• Genetic Therapy
• Immunoprecipitation
• Injections, Intraperitoneal
• Male
• Mice
• Mice, Inbred NOD
• Mitogen-Activated Protein Kinase 8 (antagonists & inhibitors)
• Molecular Sequence Data
• Peptides (administration & dosage, pharmacology, therapeutic use)
• Transfection